Search

Your search keyword '"Velkovski-Rouyer, Maja"' showing total 10 results
Start Over Author "Velkovski-Rouyer, Maja"
10 results on '"Velkovski-Rouyer, Maja"'

2. Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD

Author

Massy, Ziad A., primary, Ferrières, Jean, additional, Bruckert, Eric, additional, Lange, Céline, additional, Liabeuf, Sophie, additional, Velkovski-Rouyer, Maja, additional, Stengel, Bénédicte, additional, Ayav, Carole, additional, Combe, Christian, additional, Fouque, Denis, additional, Frimat, Luc, additional, Herpe, Yves-Edouard, additional, Laville, Maurice, additional, Massy, Ziad, additional, Legrand, Karine, additional, Metzger, Marie, additional, Speyer, Elodie, additional, Moulin, Bruno, additional, Lebrun, Gaétan, additional, Magnant, Éric, additional, Choukroun, Gabriel, additional, Bourdenx, Jean Philippe, additional, Essig, Marie, additional, Azar, Raymond, additional, Smati, Mustafa, additional, Jamali, Mohamed, additional, Klein, Alexandre, additional, Delahousse, Michel, additional, Martin, Séverine, additional, Thervet, Eric, additional, Belenfant, Xavier, additional, Urena, Pablo, additional, Vela, Carlos, additional, Chauveau, Dominique, additional, Panescu, Viktor, additional, Glowacki, François, additional, Hoffmann, Maxime, additional, Hourmant, Maryvonne, additional, Besnier, Dominique, additional, Testa, Angelo, additional, Zaoui, Philippe, additional, Chazot, Charles, additional, Juillard, Laurent, additional, Burtey, Stéphane, additional, Keller, Adrien, additional, and Kamar, Nassim, additional

Published
2019
Full Text
View/download PDF

3. ACHIEVEMENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL EUROPEAN SOCIETY OF CARDIOLOGY TARGETS IN CHRONIC KIDNEY DISEASE: A PROSPECTIVE COHORT STUDY

Author

Massy, Ziad, Ferrieres, Jean, Bruckert, Eric, Lange, Celine, Liabeuf, Sophie, Velkovski-Rouyer, Maja, Stengel, Benedicte, Service Néphrologie/Dialyse [AP-HP Ambroise-Paré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Endocrinologie, Métabolisme et Prévention des Maladies Cardio-vasculaires [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Agence de la biomédecine [Saint-Denis la Plaine], CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, MSD France, and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay

Subjects
[SDV]Life Sciences [q-bio], education, health care economics and organizations
Abstract

56th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA) - Burden, Access and Disparities in Kidney Disease, Budapest, HUNGARY, JUN 13-16, 2019; International audience

Published
2019

6. 0186: Are coronary patients on lipid-lowering therapy in Europe achieving the recommended LDL-C target? Results from the Dyslipidemia International Study (DYSIS) II Europe

Author

Gitt, Anselm K., primary, Ferrieres, Jean, additional, Ferrari, Gaetano de, additional, Elisaf, Moses, additional, Hermans, Michel P., additional, Kiernan, Thomas, additional, Oganov, Rafael, additional, Velkovski-Rouyer, Maja, additional, Lautsch, Dominik, additional, Ashton, Veronica, additional, and Ambegaonkar, Baishali, additional

Published
2016
Full Text
View/download PDF

9. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk.

Author

Graham, Ian, Shear, Chuck, De Graeff, Pieter, Boulton, Caroline, Catapano, Alberico L, Stough, Wendy Gattis, Carlsson, Stefan C, De Backer, Guy, Emmerich, Joseph, Greenfeder, Scott, Kim, Albert M, Lautsch, Dominik, Nguyen, Tu, Nissen, Steven E, Prasad, Krishna, Ray, Kausik K, Robinson, Jennifer G, Sasiela, William J, Bruins Slot, Karsten, Stroes, Erik, Thuren, Tom, Van der Schueren, Bart, Velkovski-Rouyer, Maja, Wasserman, Scott M, Wiklund, Olov, and Zouridakis, Emmanouil

Abstract

The very high occurrence of cardiovascular events presents a major public health issue, because treatment remains suboptimal. Lowering LDL cholesterol (LDL-C) with statins or ezetimibe in combination with a statin reduces major adverse cardiovascular events. The cardiovascular risk reduction in relation to the absolute LDL-C reduction is linear for most interventions without evidence of attenuation or increase in risk at low LDL-C levels. Opportunities for innovation in dyslipidaemia treatment should address the substantial risk of lipid-associated cardiovascular events among patients optimally treated per guidelines but who cannot achieve LDL-C goals and who could benefit from additional LDL-C-lowering therapy or experience side effects of statins. Fresh approaches are needed to identify promising drug targets early and develop them efficiently. The Cardiovascular Round Table of the European Society of Cardiology (ESC) convened a workshop to discuss new lipid-lowering strategies for cardiovascular risk reduction. Opportunities to improve treatment approaches and the efficient study of new therapies were explored. Circulating biomarkers may not be fully reliable proxy indicators of the relationship between treatment effect and clinical outcome. Mendelian randomization studies may better inform development strategies and refine treatment targets before Phase 3. Trials should match the drug to appropriate lipid and patient profile, and guidelines may move towards a precision-based approach to individual patient management. Stakeholder collaboration is needed to ensure continued innovation and better international coordination of both regulatory aspects and guidelines. It should be noted that risk may also be addressed through increased attention to other risk factors such as smoking, hypertension, overweight, and inactivity.

Published
2018
Full Text
View/download PDF

10. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk.

Author

Graham I, Shear C, De Graeff P, Boulton C, Catapano AL, Stough WG, Carlsson SC, De Backer G, Emmerich J, Greenfeder S, Kim AM, Lautsch D, Nguyen T, Nissen SE, Prasad K, Ray KK, Robinson JG, Sasiela WJ, Bruins Slot K, Stroes E, Thuren T, Van der Schueren B, Velkovski-Rouyer M, Wasserman SM, Wiklund O, and Zouridakis E

Subjects
Global Health, Humans, Incidence, Risk Factors, Cardiology standards, Cardiovascular Diseases blood, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control, Drug Development standards, Hypolipidemic Agents therapeutic use, Lipids blood, Practice Guidelines as Topic
Abstract

The very high occurrence of cardiovascular events presents a major public health issue, because treatment remains suboptimal. Lowering LDL cholesterol (LDL-C) with statins or ezetimibe in combination with a statin reduces major adverse cardiovascular events. The cardiovascular risk reduction in relation to the absolute LDL-C reduction is linear for most interventions without evidence of attenuation or increase in risk at low LDL-C levels. Opportunities for innovation in dyslipidaemia treatment should address the substantial risk of lipid-associated cardiovascular events among patients optimally treated per guidelines but who cannot achieve LDL-C goals and who could benefit from additional LDL-C-lowering therapy or experience side effects of statins. Fresh approaches are needed to identify promising drug targets early and develop them efficiently. The Cardiovascular Round Table of the European Society of Cardiology (ESC) convened a workshop to discuss new lipid-lowering strategies for cardiovascular risk reduction. Opportunities to improve treatment approaches and the efficient study of new therapies were explored. Circulating biomarkers may not be fully reliable proxy indicators of the relationship between treatment effect and clinical outcome. Mendelian randomization studies may better inform development strategies and refine treatment targets before Phase 3. Trials should match the drug to appropriate lipid and patient profile, and guidelines may move towards a precision-based approach to individual patient management. Stakeholder collaboration is needed to ensure continued innovation and better international coordination of both regulatory aspects and guidelines. It should be noted that risk may also be addressed through increased attention to other risk factors such as smoking, hypertension, overweight, and inactivity.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results